

REFERENCES

- Afdhal NH, Nunes D.(2004)** Evaluation of liver fibrosis: a concise review. *Am J Gastroenterol*;99:1160–1174.
- Agnello V, De Rosa FG.(2004).** Extrahepatic disease manifestations of HCV infection: some current issues. *J Hepatol*; 40: 341–52.
- Aithal GP, Haugk B, Das S, et al.(2004).** Monitoring methotrexate induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? *Aliment Pharmacol Ther*;19:391–399.
- Akriviadis E, Botla R, Briggs W, et al. .(2000)** ; Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a doubleblind, placebo-controlled trial. *Gastroenterology*;119:1637–1648.
- Aleynik SI, Leo MA, Ma X, et al. .(1997)** ; Polyenylphosphatidylcholine prevents carbon tetrachloride-induced lipid peroxidation while it attenuates liver fibrosis. *J Hepatol*;27:554–561.
- Ank, N., West, H. & Paludan, S. R. (2006).** IFN- λ : novel antiviral cytokines. *J Interferon Cytokine Res* **26**, 373–379.
- Anon. .(1993)** ; The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group. *J Hepatol*;17:227–235.
- Antonelli A, Ferri C, Pampana A, Fallahi P, et al;(2004).** Thyroid disorders in chronic hepatitis C. *Am J Med*; 117(1): 60-1.
- Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, et al.(2004);** Thyroid disorders in chronic hepatitis C. *Am J Med.* ;117(1):10–13.
- Arthur MJ.(2000)** ;Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. *Am J Physiol Gastrointest Liver Physiol*;279:G245–249.

REFERENCES

- Asselah T, Bieche I, Narguet S, et al. .(2008)** Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. *Gut*; 57: 516–24.
- Balasubramanian A, Ganju RK, Groopman JE.(2003);** Hepatitis C virus and HIV envelope proteins collaboratively mediate interleukin-8 secretion through activation of p38 MAP kinase and SHP2 in hepatocytes. *J Biol Chem.* ;278(37):35755–35766.
- Balasubramanian A, Ganju RK, Groopman JE.(2006);** Signal transducer and activator of transcription factor 1 mediates apoptosis induced by hepatitis C virus and HIV envelope proteins in hepatocytes. *J Infect Dis.* ;194(5):670–681
- Ban Y, Davies TF, Greenberg DA, Concepcion ES, Osman R, Oashi T, et al.(2004);** Arginine at position 74 of the HLA-DRb1 chain is associated with Graves' disease. *Genes Immun.* ;5:203–208
- Bataller R, Brenner DA.(2005) ;** Liver fibrosis. *J Clin Invest*;115:209–218.
- Becker DV, Bigos ST, Gaitan E, et al. .(1993) ;** Optimal use of blood tests for assessment of thyroid function. *Thyroid.* 1993;3:353–354.
- Bedossa P, Poinard T, The French METAVIR Cooperative Study Group (1996):** An algorithm for grading activity in chronic hepatitis C. *Hepatology* ;24:289–293.
- Beljaars L, Meijer DK, Poelstra K. .(2002)** Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis. *Front Biosci* ;7:e214–222.
- Bell TM, Bansal AS, Shorthouse C, Sandford N, Powell EE. .(1999) ;** Low-titre auto-antibodies predict autoimmune disease during

REFERENCES -----

interferon-alpha treatment of chronic hepatitis C. *J Gastroenterol Hepatol*; 14:419–22.

Benelhadj S, Marcellin P, Castelnau C, Colas-Linhart N, Benhamou JP, Erlinger S, Bok B. .(1997) ; Incidence of dysthyroidism during interferon therapy in chronic hepatitis C. *Horm Res*; 48:209–14.

Benyon D, Arthur MJP(2001); Extracellular matrix degradation and the role of stellate cells. *Semin Liver Dis* ;21:373–384.

Berg T, von Wagner M, Nasser S, et al. .(2006) ; Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. *Gastroenterology*; **130**: 1086–97

Bianchi GP, Zoli M, Marchesini G, Volta U, Vecchi F, Iervese T, Bonazzi C, Pisi E. .(1991) ;Thyroid gland size and function in patients with cirrhosis of the liver. *Liver* ;11:71–7

Biondi B, Palmieri EA, Fazio S, et al. .(2000) ; Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. *J Clin Endocrinol Metab.*;85:4701-4705.

Blackard JT, Kemmer N, Sherman KE.(2006); Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. *Hepatology.* ;44(1):15–22

Bogazzi F, Bartalena L, Martino E. .(2000); Color flow Doppler sonography of the thyroid. In: Baskin HJ, ed. *Thyroid Ultrasound and Ultrasound-Guided FNA Biopsy*. Boston: Kluwer Academic Publishers, : 227-229.

REFERENCES -----

- Bressanelli S, Tomei L, Roussel A, et al. .(1999)** Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. *Proc Natl Acad Sci USA* ; **96**: 13034–39.
- Brideau-Andersen, A. D., Huang, X., Sun, S. C., Chen, T. T., Stark, D., Sas, I. J., Zadik, L., Dawes, G. N., Guptill, D. R. & other authors (2007).** Directed evolution of gene-shuffled IFN- α molecules with activity profiles tailored for treatment of chronic viral diseases. *Proc Natl Acad Sci U S A* **104**, 8269–8274.
- Bruck R, Frenkel D, Shirin H, Aeed H, Matas Z, Papa M, Zaidel L, Avni Y, Oren R, Halpern Z. .(1999);** Hypothyroidism protects rat liver from acetaminophen hepatotoxicity. *Dig Dis Sci* 1999; 44:1228–35.
- Bruck R, Genina O, Aeed H, et al.(2001);.** Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. *Hepatology*;33:379–386.
- Callewaert N, Van Vlierberghe H, Van Hecke A, et al. .(2004) ;** Noninvasive diagnosis of liver cirrhosis using DNA sequencerbased total serum protein glycomics. *Nature Med*;10:429–434.
- Canbay A, Higuchi H, Bronk SF, et al (2002).** Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. *Gastroenterology*;123:1323–1330.
- Canbay A, Taimr P, Torok N, et al(2003).** Apoptotic body engulfment by a human stellate cell line is profibrogenic. *Lab Invest*;83:655–663.
- Chalasani N, Imperiale TF, Ismail A, et al. .(1999);** Predictors of large esophageal varices in patients with cirrhosis. *Am J Gastroenterol* 1999;94:3285–3291.

REFERENCES

- Chevaliez S, Pawlotsky JM. .(2007)** ; Hepatitis C virus: virology, diagnosis and management of antiviral therapy. *World J Gastroenterol*; 13: 2461–66.
- Choudhary AM, Roberts I .(1999)**; Thyroid storm presenting with liver failure. *J Clin Gastroenterol*; 29:318–21.
- Chu JW, Crapo LM. .(2001)** ; The treatment of subclinical hypothyroidism is seldom necessary. *J Clin Endocrinol Metab.* ;86:4591-4599.
- Chuang WC, Sarkodie F, Brown CJ, et al. .(2007)** ; Protective effect of HLAB57 on HCV genotype 2 infection in a West African population. *J Med Virol* ; 79: 724–33.
- Chung YH, Jung SA, Song BC, Chang WY, Kim JA, Song IH, Kim JW, Choi WB, Shong YK, Lee YS, Suh DJ. .(2001)** ; Plasma isocitrate dehydrogenase as a marker of centrilobular hepatic necrosis in patients with hyperthyroidism. *J Clin Gastroenterol*; 33:118–22.
- Codes L, Asselah T, Cazals-Hatem D, et al. .(2007)** ; Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy. *Gut*; 56: 390–95.
- Colloredo G, Guido M, Sonzogni A, Leandro G. .(2003)** ; Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. *J Hepatol*;39:239–244.
- Cooper DS.(1991).** Treatment of thyrotoxicosis. In: Braverman LE, Utiger RD, eds. *Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text*. 6th ed. Philadelphia: JB Lippincott Co.; 887-916.

REFERENCES -----

- Cooper DS.(2001);** Clinical practice: subclinical hypothyroidism. *N Engl J Med.* 2001;345:260-265.
- Croft AM, Herxheimer A. .(2002) ;** Adverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement? *BMC Public Health*; 2:6.
- D’Antonio A, Franco R, Sparano L, Terzi G, Pettinato G. .(2000) ;** Amyloid goiter: the first evidence in secondary amyloidosis: report of five cases and review of literature. *Adv Clin Path*; 4:99–106.
- Danese MD, Ladenson PW, Meinert CL, Powe NR. .(2000) ;**Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure; a quantitative review of the literature. *J Clin Endocrinol Metab.*;85:2993-3001.
- Daniel P Webster, Paul Klenerman, Jane Collier, Katie J M Jeffery .(2009) ;** Development of novel treatments for hepatitis C *Lancet Infect Dis*; 9: 108–17
- Danta M, Brown D, Bhagani S, et al. .(2007) ;** Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. *AIDS*; 21: 983–91.
- Davis GL, Albright JE, Cook SF, Rosenberg DM. .(2003) ;** Projecting future complications of chronic hepatitis C in the United States. *Liver Transpl*; 9: 331–38.
- De Clercq E. .(2004) ;** Antivirals and antiviral strategies. *Nat Rev Microbiol*; 2: 704–20.
- De Rosa FG, Bargiacchi O, Audagnotto S, et al. .(2007) ;** Twelve-week treatment of acute hepatitis C virus with pegylated interferon-alpha -2b in injection drug users. *Clin Infect Dis*; **45**: 583–88.)
- Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess G,Horsch A, Hadziyannis S. .(1997) ;** Thyroid abnormalities in chronic viral

REFERENCES -----

hepatitis and their relationship to interferon alfa therapy. *Hepatology*; 26:206–10.

Dev A, White I, Symonds W, et al. .(2005) ; Serum proteomic analysis in hepatitis C patients with and without fibrosis. *J Hepatol* ;42(suppl 2):117A.

Dickson ER, Fleming TR, Wiesner RH, et al. .(1985) ; Trial of penicillamine in advanced primary biliary cirrhosis. *N Engl J Med* ;312:1011–1015.

Dufour JF, DeLellis R, Kaplan MM. .(1997); Reversibility of hepatic fibrosis in autoimmune hepatitis. *Ann Intern Med*;127:981–985.

El-Serag HB.(2002); Hepatocellular carcinoma and hepatitis C in the United States. *Hepatology* ;36(Suppl 1):S74–83.

Faber J, Jensen IW, Petersen L, Nygaard B, Hegedus L, Siersbaek-Nielsen K. .(1998) ; Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. *Clin Endocrinol (Oxf)*.;48:285-290.

Fang X, Zeisel MB, Wilpert J, Gissler B, Thimme R, Kreutz C, et al.(2006); Host cell responses induced by hepatitis C virus binding. *Hepatology*. ;43(6):1326–1336

Farwell AP, Braverman LE. .(1996); Thyroid and antithyroid drugs. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. 9th ed. New York: McGraw-Hill,: 1383-1409.

Fattovich G, Giustina G, Degos F, et al.(1997) ; Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. *Gastroenterology* ;112:463–472.

REFERENCES -----

- Fattovich G, Giustina G, Favarato S, Ruol A. .(1996);** A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. *J Hepatol*; 24: 38–47.
- Forns X, Ampurdanes S, Llovet JM, et al. .(2002) ;** Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. *Hepatology* ;36:986–992.
- Fournie GJ, Mas M, Cautain B, Savignac M, Subra JF, Pelletier L, et al.(2001);** Induction of autoimmunity through bystander effects. Lessons from immunological disorders induced by heavy metals. *J Autoimmun.* ;16(3):319–326.
- Franklyn JA. .(1994) ;** The management of hyperthyroidism . *N Engl J Med.*; 330:1731-1738.
- Freeman JA, Heffernan J, Klucher K, et al. .(2006) ;** Assessment of the pharmacological activity of pegylated recombinant interleukin-29 (PEG-rIL-29) in cynomolgus monkeys. *Hepatology* ; 44 (suppl 1): A534.)
- Friedman SL.(2000);** Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. *J Biol Chem* ;275:2247–2250.
- Gaca MD, Pickering JA, Arthur MJ, Benyon RC.(1999);** Human and rat hepatic stellate cells produce stem cell factor: a possible mechanism for mast cell recruitment in liver fibrosis. *J Hepatol* ;30:850–858.
- Galossi A, Guarisco R, Bellis L, Puoti C.(2007);** Extrahepatic manifestations of chronic HCV infection. *J Gastrointest Liver Dis*; 16: 65–73.)
- Geerts A.(2001) ;** History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. *Semin Liver Dis*;21:311–335.

REFERENCES

- Gharib H, Mazzaferri EL.(1998);** Thyroxine suppressive therapy in patients with nodular thyroid disease. *Ann Intern Med.*;128:386-394.
- Giannini E, Testa R.(2003);** Noninvasive diagnosis of fibrosis: the truth is rarely pure and never simple. *Hepatology* ;38:1312–1313 .
- Gish RG, Arora S, Rajender Reddy K, et al.(2007);** Virological response and safety outcomes in therapy-naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. *J Hepatol*; **47**: 51–59.
- Gravante G, Delogu D, Rizzello A, Filingeri V.(2007);** The Zuckerkandl tubercle. *Am J Surg.* Apr ;193(4):484-5.
- Gressner AM, Weiskirchen R, Breitkopf K, Dooley S(2002);** Roles of TGF-beta in hepatic fibrosis. *Front Biosci* , 7:D793–807.
- Hadziyannis SJ, Sette H Jr, Morgan TR, et al. .(2004) ;** Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* ; **140**: 346–55.
- Han YP, Zhou L, Wang J, et a.l(2004);** Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. *J Biol Chem* ;279:4820–4828.
- Hegedus L.(1986);** Thyroid gland volume and thyroid function during and after acute hepatitis infection. *Metabolism*; 35:495–8.
- Helfand M, Redfern CC.(1999);** Clinical guideline, part 2: screening for thyroid disease; an update. American College of Physicians. *Ann Intern Med.* 1998;129:144-158.
- Hillebrandt S, Goos C, Matern S, Lammert F.(2002);** Genome-wide analysis of hepatic fibrosis in inbred mice identifies the

REFERENCES

- susceptibility locus Hfib1 on chromosome 15. *Gastroenterology* ;123:2041–2051.
- Huang Z, Murray MG, Secrist JA.(2006);** . Recent development of therapeutics for chronic HCV infection. *Antiviral Res*; **71**: 351–62.)
- Ikeda K, Wang LH, Torres R, et al.(2002).** Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen. *J Biol Chem* ;277:19206–19212.
- Inkinen J, Sand J, Nordback I.(2000);** Association between common bile duct stones and treated hypothyroidism. *Hepatogastroenterology* ; 47:919–21.
- Iredale JP.(2001);** Stellate cell behavior during resolution of liver injury. *Semin Liver Dis* ;21:427–436.
- Isaacs, A. & Lindenmann, J. (1957).** Virus interference. I. The interferon. *Proc R Soc Lond B Biol Sci* **147**, 258–267.
- Isaka Y, Brees DK, Ikegaya K, et al.(1996);** Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. *Nature Med*;2:418–423.
- Issa R, Williams E, Trim N, et al.(2001);** Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. *Gut*;48:548–557.
- Jain S, Goharkhay N, Saade G, Hankins GD, Anderson GD.(2007);** Hepatitis C in pregnancy. *Am J Perinatol*; 24: 251–56.
- Jarnagin WR, Rockey DC, Koteliensky VE, et al.(1994);** Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. *J Cell Biol* ;127:2037–2048.
- Kalinichenko VV, Bhattacharyya D, Zhou Y, et al.(2003);** Foxf1 +/- mice exhibit defective stellate cell activation and abnormal liver regeneration following CCl4 injury. *Hepatology* ;37:107–117.

REFERENCES -----

- Kalluri R, Neilson EG.(2003);** Epithelial–mesenchymal transition and its implications for fibrosis. *J Clin Invest* ;112: 1776–1784.
- Kamada Y, Tamura S, Kiso S, et al.(2003);** Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. *Gastroenterology*;125:1796–1807.
- Kano T, Kojima T, Takahashi T, Muto Y.(1987);** Serum thyroid hormone levels in patients with fulminant hepatitis: usefulness of rT3 and the rT3/T3 ratio as prognostic indices. *Gastroenterol Jpn* ; 22:344–53.
- Kim HJ, Kim BH, Han YS, Yang I, Kim KJ, Dong SH, Kim HJ, Chang YW, Lee JI, Chang R.(2001);** The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: a single-center retrospective study. *Am J Gastroenterol* 2001; 96:165–9.
- Kim WR, Brown RS Jr, Terrault NA, El-Serag H.(2002);** Burden of liver disease in the United States: summary of a workshop. *Hepatology* , 36:227–242.
- Kinney EL, Wright RJ, Caldwell JW.(1989);** Value of clinical features for distinguishing myxedema ascites from other forms of ascites. *Comput Biol Med* ; 19:55–9.
- Klenerman P, Kim A.(2007);** HCV-HIV coinfection: simple messages from a complex disease. *PLoS Med* ; 4: e240.
- Kobayashi S, Seki S, Kawada N, et al.(2003);** Apoptosis of T cells in the hepatic fibrotic tissue of the rat: a possible inducing role of hepatic myofibroblast-like cells. *Cell Tissue Res*;311:353–364.
- Krawitt E(1996)L.** Autoimmune hepatitis. *N Engl J Med* ;334:897–903.
- Landau DA, Saadoun D, Calabrese LH, Cacoub P.(2007);** The pathophysiology of HCV induced B-cell clonal disorders. *Autoimmun Rev.* ;6(8):581–587.

REFERENCES -----

- Lang A, Schoonhoven R, Tuvia S, et al.(2000);** Nuclear factor kappaB in proliferation, activation, and apoptosis in rat hepatic stellate cells. *J Hepatol*;33:49–58.
- Larsen PR, Davies TF, Hay ID.(1998);** The thyroid gland. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds.*Williams Textbook of Endocrinology*. 9th ed. Philadelphia:WB Saunders Co,: 389-515.
- Laskus T, Radkowski M, Wang LF, Vargas H, Rakela J.(1998);** Search for hepatitis C virus extrahepatic replication sites in patients with acquired immunodeficiency syndrome: specific detection of negative-strand viral RNA in various tissues. *Hepatology*. ;28(5):1398–1401.
- Leeson TS, Leeson CR, Daparo AA.(1988);** The endocrine system. In: Text/Atlas of Histology. St. Louis, Mo.: Harcourt Health Sciences Group;:579-84.
- Li L, Tao J, Davaille J, et al.(2001);** 15-deoxy-delta 12,14- prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors. *J Biol Chem*;276:38152–38158.
- Lieber CS, Leo MA, Cao Q, et al.(2003);** Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. *J Clin Gastroenterol* ;37:336–339.
- Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH.(1992);** Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. *Gastroenterology*.; **102** (6): 2155-60.
- Liu C, Gaca MD, Swenson ES, et al.(2003);** Smads 2 and 3 are differentially activated by transforming growth factor-beta

REFERENCES -----

- (TGF-beta) in quiescent and activated hepatic stellate cells. Constitutive nuclear localization of Smads in activated cells is TGF-beta-independent. *J Biol Chem*;278: 11721–11728.
- Lu SC, Tsukamoto H, Mato JM.(2002);** Role of abnormal methionine metabolism in alcoholic liver injury. *Alcohol* 2002;27:155–162.
- Magness ST, Bataller R, Yang L, Brenner DA.(2004);** A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. *Hepatology* ;40: 1151–1159.
- Malik R, Mellor N, Selden C, Hodgson H.(2000);** Characterising the effects of thyroid hormone on the liver: a novel approach to increase liver mass. *Gut*; 34 (Suppl. 1):78.
- Malik R. and Hodgson H. (2002).** the relationship between the thyroid gland and the liver *q j med* ; 95:559-569
- Mann DA, Smart DE.(2002)** Transcriptional regulation of hepatic stellate cell activation. *Gut* ;50:891–896.
- Marcellin P, Chang TT, Lim SG, et al.(2003);** Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. *N Engl J Med* 2003;348:808–816.
- Maribel rodriguez-torres ; carlos f. Rios-bedoya ; grisell ortiz-lasanta; Acisclo m marxuach-cuetara et al ;(2008).** thyroid dysfunction (td) among chronic Hepatitis c patients with mild and severe hepatic fibrosis *annals of hepatology* ; 7(1): January-march: 72-77
- Mario Rotondi, Roberta Minellil, Flavia Magri, Paola Leporati, et al; (2007).** Serum CXCL10 levels and occurrence of thyroid dysfunction in patients treated with interferon-a therapy for hepatitis C virus-related hepatitis *European Journal of Endocrinology* ,156 409-414
- Marra F.(2002);** Chemokines in liver inflammation and fibrosis. *Front Biosci* ;7:d1899–914.
- Mazzioiti G, Sorvillo F, Piscopo M, Morisco F, et al; (2005).**Innate and acquired immune system in patients developing interferon-

REFERENCES

- alpha-related autoimmune thyroiditis: a prospective study. *Journal of Clinical Endocrinology and Metabolism* , 90 4138-144.
- Mazzocca A, Carloni V, Sciammetta S, et al.(2002)** ; Expression of transmembrane 4 superfamily (TM4SF) proteins and their role in hepatic stellate cell motility and wound healing migration. *J Hepatol* ;37:322–330.
- McCoul ED, de Vries EJ.(2009)**; Concurrent lingual thyroid and undescended thyroglossal duct thyroid without orthotopic thyroid gland. *Laryngoscope*. Oct 2009;119(10):1937-40.
- McDermott MT, Ridgway EC.(2001)**; Subclinical hypothyroidism is mild thyroid failure and should be treated. *J Clin Endocrinol Metab.*;86:4585-4590.
- McEvoy GK.(1994)**; *AHFS Drug Information 94*. Bethesda, MD: American Hospital Formulary Service,: 2101.
- McHutchison JG, Bacon BR, Gordon SC, et al.(2007)**; Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. *Hepatology*; **46**: 1341–49.)
- McIntyre PG, Tosh K, McGuire W.(2006)**; Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission. *Cochrane Database Syst Rev*; 4: CD005546.
- Meager, A., Visvalingam, K., Dilger, P., Bryan, D. & Wadhwa, M. (2005)**. Biological activity of interleukins-28 and -29: comparison with type I interferons. *Cytokine* **31**, 109–118.
- Melman ML.(1994)**: Interferon-alpha in the treatment of chronic viral hepatitis. *Rev Gastroenterol Mex*; 59:46–8.
- Meurs EF, Breiman A. .(2007)** ; The interferon inducing pathways and the hepatitis C virus. *World J Gastroenterol* ; **13**: 2446–54

REFERENCES -----

- Moucari R, Asselah T, Cazals-Hatem D, et al.(2008);** Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. *Gastroenterology*; 134: 416–23.
- Muir AJ, Sylvestre PB, Rockey DC.(2006);** Interferon gamma-1b for the treatment of chronic hepatitis C infection. *J Viral Hepatitis*; in press.
- Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC.(1994);** Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest. *Dig Dis Sci*;39:2426–2432.
- Naveau S, Raynard B, Ratziu V, et al.(2005);** Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. *Clin Gastroenterol Hepatol* ;3:167–174.
- Nelson DR, Tu Z, Soldevila-Pico C, et al.(2003);** Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. *Hepatology* ;38:859–868.
- Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al.(2003);** Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. *Hepatology* ;38:1008–1017.
- Neyts J.(2006);** Selective inhibitors of hepatitis C virus replication. *Antiviral Res*; **71**: 363–71
- O'Donnell AL, Spaulding SW.(1997);** Hyperthyroidism: systemic effects and differential diagnosis. In: Falk SA, ed. *Thyroid Disease: Endocrinology, Surgery, Nuclear Medicine, and Radiotherapy*. 2nd ed. Philadelphia: Lippincott-Raven Publishers,: 241-252.
- Ohata M, Yamauchi M, Takeda K, et al.(2000);** RAR and RXR expression by Kupffer cells. *Exp Mol Pathol* ; 68:13–20.

REFERENCES

- Olaso E, Salado C, Egilegor E, et al(2003).** Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. *Hepatology*;37:674–685.
- Onoguchi, K., Yoneyama, M., Takemura, A., Akira, S., Taniguchi, T., Namiki, H. & Fujita, T. (2007).** Viral infections activate types I and III interferon genes through a common mechanism. *J Biol Chem* **282**, 7576–7581.
- Oren R, Sikuler E, Wong F, Blendis LM, Halpern Z.(2000);** The effects of hypothyroidism on liver status of cirrhotic patients. *J Clin Gastroenterol* ; 31:162–3.
- Patel K, Gordon SC, Jacobson I, et al. .(2004)** ; Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. *J Hepatol* ;41:935–942.
- Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. .(2004)** ; Structural biology of hepatitis C virus. *Hepatology* ; 39: 5-19
- Pinzani M, Marra F.(2001);** Cytokine receptors and signaling in hepatic stellate cells. *Semin Liver Dis* ;21:397–416.
- Pohlmann S, Zhang J, Baribaud F, et al.(2003);** Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. *J Virol* ;77:4070–4080.
- Poordad F, Reddy KR, Martin P.(2008);** Rapid virologic response: a new milestone in the management of chronic hepatitis C. *Clin Infect Dis* ; **46**: 78–84.
- Poynard T, Imbert-Bismut F, Munteanu M, et al. .(2004)** ; Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. *Comp Hepatol* ;3:8.
- Poynard T, Marcellin P, Lee SS, et al.(1998);** Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks

REFERENCES -----

versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. *Lancet*; 352: 1426–32.

Poynard T, Ratziu V, Charlotte F, et al.(2001); Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. *J Hepatol* ;34:730–739.

Poynard T, Yuen MF, Ratziu V, Lai CL.(2003); Viral hepatitis C. *Lancet* ; 362: 2095–100.

Prummel MF, Laurberg P. (2003); Interferon Alfa and autoimmune thyroid disease. *Thyroid*; 13(6): 547-51.

Rambaldi A, Gluud C.(2001); Meta-analysis of propylthiouracil for alcoholic liver disease – a Cochrane Hepato-Biliary Group Review. *Liver* ;21:398–404.

Ratzu V, Charlotte F, Heurtier A, et al.(2005); Sampling variability of liver biopsy in nonalcoholic fatty liver disease. *Gastroenterology*;128:1898–1906.

Reesink HW, Zeuzem S, Weegink CJ, et al.(2006); Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. *Gastroenterology*; 131: 997–1002.

Reinehr RM, Kubitz R, Peters-Regehr T, et al(1998). Activation of rat hepatic stellate cells in culture is associated with increased sensitivity to endothelin 1. *Hepatology*;28:1566–1577.

Roberts EA, Yeung L.(2002); Maternal-infant transmission of hepatitis C virus infection. *Hepatology*; 36 (5 suppl 1): S106–13.

Rockey DC, Fouassier L, Chung JJ, et al.(1998); Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. *Hepatology* , 27:472–480.

Rockey DC.(2003); Vascular mediators in the injured liver. *Hepatology* ;37:4–12.

REFERENCES

- Rodriguez L, Cerbon-Ambriz J, Munoz ML.(1998);** Effects of colchicine and colchicine in a biochemical model of liver injury and fibrosis. *Arch Med Res* ;29:109–116.
- Roti E, Minelli R, Giuberti T, Marchelli S, Schianchi C, Gardini E, Salvi M, Fiaccadori F, Ugolotti G, Neri TM, Braverman LE.(1996);** Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. *Am J Med* ; 101:482–7.
- Rousselet MC, Michalak S, Dupre F, et al.(2005);** Sources of variability in histological scoring of chronic viral hepatitis. *Hepatology* ;41:257–264.
- Rustgi VK.(2007);** The epidemiology of hepatitis C infection in the United States. *J Gastroenterol*; 42: 513–21.
- Saadoun D, Asselah T, Resche-Rigon M, et al.(2006);** Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. *Hepatology* ; **43**: 1337–45.
- Saarinen S, Olerup O, Broome U.(2000);** Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. *Am J Gastroenterol* ; 95:3195–9.
- Safadi R, Ohta M, Alvarez CE, et al.(2004);** Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. *Gastroenterology* ;127: 870–882.
- Saxena NK, Saliba G, Floyd JJ, Anania FA. .(2003);** Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells. *J Cell Biochem* ;89:311–320.
- Schaefer B, Rivas-Estilla AM, Meraz-Cruz N, et al.(2003);** Reciprocal modulation of matrix metalloproteinase-13 and type I collagen genes in rat hepatic stellate cells. *Am J Pathol* ;162:1771–1780.
- Schiff ER.(2007);** Emerging strategies for pegylated interferon combination therapy. *Nat Clin Pract Gastroenterol Hepatol* ; **4** (suppl 1): S17–21.

REFERENCES

- Schnabl B, Kweon YO, Frederick JP, et al(2001).** The role of Smad3 in mediating mouse hepatic stellate cell activation. *Hepatology* ;34:89–100.
- Schuppan D, Ruehl M, Somasundaram R, Hahn EG.(2001) ;** Matrix as modulator of stellate cell and hepatic fibrogenesis. *Semin Liver Dis* ;21:351–372.
- Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A.(2005);** Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. *Hepatology*; 42: 962-973
- Sohara N, Znoyko I, Levy MT, et al.(2002);** Reversal of activation of human myofibroblast-like cells by culture on a basement membrane-like substrate. *J Hepatol*;37:214–221.
- Spahr L, Rubbia-Brandt L, Pugin J, et al.(2001);** Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood. *J Hepatol*;35:582–589.
- Stéphane Chevaliez, Jean-Michel Pawlotsky (2007)** *World J Gastroenterol* , May 7; 13(17): 2461-2466
- Stewart S, Prince M, Bassendine M, et al.(2002);** A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. *J Hepatol* ;36(S):16.
- Thieblemont C, Mayer A, Dumontet C, Barbier Y, Callet-Bauchu E, Felman P, Berger F, Ducottet X, Martin C, Salles G, Orgiazzi J, Coiffier B.(2002);** Primary thyroid lymphoma is a heterogeneous disease. *J Clin Endocrinol Metab* ; 87:105–11.

REFERENCES -----

- Thobe N, Pilger P, Jones MP.(2000);** Primary hypothyroidism masquerading as hepatic encephalopathy: case report and review of the literature. *Postgrad Med J* ; 76:424–6.
- Thompson K, Maltby J, Fallowfield J, et al.(1998);** Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. *Hepatology* ;28:1597–1606.
- Thorpe LE, Ouellet LJ, Hershow R, et al.(2002);** Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. *Am J Epidemiol* ; 155: 645–53)
- Toft AD.(2001);** Clinical practice: subclinical hyperthyroidism. *N Engl J Med.* ;345:512-516.
- Tomer Y, Davies TF.(1993);** Infection, Thyroid Disease and Autoimmunity. *Endocr Rev.* ;14:107–120.
- Toubi E, Gordon S, Kessel A, Rosner I, Rozenbaum M, Shoenfeld Y, et al.(2006);** Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. *J Autoimmun.* ;27(2):134–139.
- Tran HA, Jones TL, Batey RG. (2005).** The spectrum of thyroid dysfunction in an Australian hepatitis c population treated with combination Interferon alpha and Ribavirin. *BMC Endocr Disord*; 5:8.
- Trim N, Morgan S, Evans M, et al.(2000);** Hepatic stellate cells express the low affinity nerve growth factor receptor p75 and undergo apoptosis in response to nerve growth factor stimulation. *Am J Pathol* ;156:1235–1243.
- Tsukamoto H.(2002);** Redox regulation of cytokine expression in Kupffer cells. *Antioxid Redox Signal*;4:741–748.
- Utiger RD.(1989);** Hypothyroidism. In: DeGroot LJ, ed. *Endocrinology*. Vol 1. 2nd ed. Philadelphia: WB Saunders Co, : 702-721.
- van Santen HM, de Kraker J, van Eck BL, de Vijlder JJ,Vulsma T.(2002);** High incidence of thyroid dysfunction despite

REFERENCES -----

prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma. Cancer ; 94:2081–9.

Van Thiel DH, Udani M, Schade RR, Sanghvi A, Starzl TE.(1985);Prognostic value of thyroid hormone levels in patients evaluated for liver transplantation. Hepatology; 5:862–6.

Vogel W, Gish GD, Alves F, Pawson T.(1997). The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell ;1:13–23.

Wack A, Soldaini E, Tseng C, Nuti S, Klimpel G, Abrignani S.(2001); Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur J Immunol. ;31(1):166–175.

Wai CT, Greenson JK, Fontana RJ, et al. .(2003); A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38: 518–526.

Wells RG.(2005); The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. J Clin Gastroenterol;39:S158–161.

Wright MC, Issa R, Smart DE, et al.(2001); Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001;121:685–698.

Yata Y, Gotwals P, Kotliansky V, Rockey DC.(2002); Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. Hepatology ;35:1022–1030.

REFERENCES -----

Zignego AL, Craxì A.(2008); Extrahepatic manifestations of hepatitis C virus infection. *Clin. Liver Dis.*; **12**: 611–36.